

**ASX Announcement**

**12 October 2021**

**Prof. Ricky Sharma appointed to the Board of OncoSil**

**Sydney, Australia – 12 October 2021:** The Board of OncoSil Medical Ltd (ASX: OSL) (**OncoSil** or the **Company**) is pleased to announce the appointment of Professor Ricky Sharma to the OncoSil Board as a Non-Executive Director effective 1 November 2021.

Professor Sharma is an international authority on the translation of radiobiology from the laboratory to the clinic and on the multi-modality treatment of cancer with precision radiotherapy. He is currently Vice President Clinical Affairs at Varian, a Siemens Healthineers company.

Professor Sharma is also an honorary consultant in clinical oncology at University College London Hospitals, where he has a clinical practice in radiotherapy and chemotherapy. He has led a research team at University College London that translated discoveries in radiotherapy research to clinical trials to improve treatment for patients with cancer.

Professor Sharma was previously an associate professor at the University of Oxford, and an honorary consultant in clinical oncology at Oxford University Hospitals. He has over 200 publications in peer-reviewed scientific journals, including *Lancet* and *Nature* journals.

Professor Sharma has previously been the chair of radiation oncology at University College London and a scientific group leader at the UCL Cancer Institute and he was a former chair of working groups for NHS/NICE evaluations of novel radiotherapy treatments.

He graduated in medicine from the University of Cambridge, United Kingdom. He trained in general internal medicine, medical oncology and radiation oncology and completed a PhD on DNA damage repair.

**Professor Ricky Sharma commented:**

*“I believe that OncoSil has the ability to rapidly transform the way pancreatic cancer is treated for future patients. I am looking forward to providing the OncoSil team with my perspective and insights on commercialisation and clinical advancement.”*

**OncoSil’s Chair, Dr Chris Roberts said:**

*“We are privileged to have such an experienced clinician joining the team. Ricky’s experience in radiotherapies and oncology will enhance our expertise as we bring the OncoSil device to market, and further develop market opportunities for the company.”*

**Authorisation & Additional Information**

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

Company	Company
<p><b>Mr Nigel Lange</b> CEO &amp; Managing Director E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a> T: +49 30 300 149 3043</p>	<p><b>Mr Karl Pechmann</b> CFO &amp; Company Secretary E: <a href="mailto:karl.pechmann@oncosil.com">karl.pechmann@oncosil.com</a> T: +61 2 9223 3344</p>

## About OncoSil

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted six clinical studies with positive results on tolerability, safety and efficacy. CE Marking has been granted for the OncoSil™ device which can be marketed in the European Union and the United Kingdom. The OncoSil™ device has also been classified a Breakthrough Device in the European Union and the United Kingdom.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval.

In December 2018, the FDA granted Humanitarian Use Designation (HUD) for the OncoSil™ device for the treatment of unresectable bile duct cancer. In March 2020, the FDA granted Breakthrough Device Designation for the OncoSil™ for unresectable pancreatic cancer in conjunction with systemic chemotherapy.

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$3b.

## Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.